This post kicks off our new series, Truveta experts— a spotlight on the data scientists, researchers, clinicians, and analysts working behind the scenes to drive healthcare research forward with real-world data. Our first contributor is Mantas Dmukauskas, PhD, a...
A new peer-reviewed study from researchers at Saint Luke’s Mid America Heart Institute, Impulse Dynamics, and the Cardiovascular Research Foundation demonstrates the power of real-world data to evaluate device therapies. By evaluating survival outcomes of cardiac...
Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease, making early detection more accessible than ever. The Lumipulse test measures biomarkers in the blood associated with Alzheimer’s pathology, offering a simpler alternative to...
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
